文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

重症患者医院获得性肺炎相关代谢特征及干扰素-γ治疗反应的识别

Identification of a robust metabolic signature associated with hospital-acquired pneumonia and response to interferon-gamma treatment in critically ill patients.
PubMed 文献 · Crit Care · 2026-03-12
一句话结论纵向聚类可将重症脑损伤患者的代谢反应分为低、中、高风险三组,HAP发生率分别为24%、60%、78%,并可能帮助识别干扰素γ-1b的应答者。

研究基于法国两个中心的前瞻性观察队列,对128例脑损伤重症患者在入组第1天、第3-4天和第6-7天进行血液代谢组学检测,用无监督纵向共识聚类分类代谢反应模式,并将发现队列训练的Fast-and-Frugal Tree应用于PREV-HAP随机临床试验的复制数据集(105例患者,315份样本)。结果显示,基于脂肪酸代谢相关代谢物可识别三种代谢反应模式,HAP发生率分别为24%、60%和78%,ARDS发生率分别为6%、16%和43%;复制数据集中三种模式的HAP发生率分别为18%、28%和40%。干扰素γ-1b单次注射后,低风险代谢模式患者活着转出ICU的概率降低,高风险代谢模式患者该概率升高。作者认为纵向聚类有助于识别HAP风险及干扰素γ-1b的应答者与非应答者。

要点

  • 基于脂肪酸代谢相关代谢物,重症脑损伤患者可被纵向聚类分为三种代谢反应模式,HAP发生率分别为24%、60%和78%,ARDS发生率分别为6%、16%和43%。
  • 复制数据集(105例患者,315份样本)中三种代谢模式的HAP发生率分别为18%、28%和40%,与发现队列的代谢物时间趋势及HAP关联具有相似性。
  • 干扰素γ-1b单次注射后,低风险代谢反应模式患者活着转出ICU的概率降低,高风险代谢反应模式患者该概率升高。
  • 作者结论认为,纵向聚类可将代谢反应模式分为HAP低、中、高风险组,并可能帮助识别干扰素γ-1b的应答者与非应答者。

适用人群与场景

  • 发现队列:法国两个中心的前瞻性观察队列中的脑损伤重症患者,第1天、第3-4天和第6-7天采集血代谢组学样本。
  • 复制数据集:来自PREV-HAP随机临床试验的重症患者,该试验测试干扰素γ-1b预防HAP。

研究设计与关键结果

  • 研究类型:前瞻性观察队列(发现队列,法国两个中心)加随机临床试验复制数据集(PREV-HAP试验)的代谢组学分析。
  • 发现队列共128例患者、330份样本,其中57例(45%)发生HAP,21例(16%)发生ARDS。
  • 基于脂肪酸代谢相关代谢物识别出三种代谢反应模式,HAP发生率分别为24%、60%和78%,ARDS发生率分别为6%、16%和43%。
  • 复制数据集共105例患者、315份样本,三种代谢模式的HAP发生率分别为18%、28%和40%。
  • 干扰素γ-1b单次注射后,低风险代谢反应模式患者活着转出ICU的概率降低,高风险代谢反应模式患者活着转出ICU的概率升高。

证据类型、等级与局限

  • 证据类型:前瞻性观察队列的代谢组学分析,并在PREV-HAP随机临床试验的复制数据集中验证代谢模式的稳健性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,纵向聚类可将代谢反应模式分为HAP低、中、高风险组,并可能帮助识别干扰素γ-1b的应答者与非应答者。

指南或共识出处

  • 临床试验注册号:ClinicalTrials.gov NCT02003196 和 NCT04793568。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: Our objective was to increase our understanding of the effects of the time course of metabolic alterations on the risk of hospital-acquired pneumonia (HAP) and response to treatment in critically ill patients.

METHODS: We first studied the blood metabolome at day 1, day 3-4 and day 6-7 of patients from a prospective, observational cohort of brain-injured patients in two French centres. We classified the metabolic response by unsupervised longitudinal consensus clustering. To evaluate the robustness of metabolic patterns, a Fast-and-Frugal Tree trained on the discovery cohort was applied to a replication dataset from the PREV-HAP randomised clinical trial testing interferon gamma-1b for the prevention of HAP in critically ill patients. The primary outcome was the association of metabolic response patterns with HAP.

FINDINGS: Of the 128 patients analysed (330 samples), 57 (45%) had developed HAP and 21 (16%) acute respiratory distress syndrome (ARDS). Based on metabolites involved in fatty acid metabolism, we identified three metabolic response patterns associated with the risks of HAP (24%, 60% and 78% of HAP, respectively) and ARDS (6%, 16% and 43%, respectively). In a replication dataset (315 samples from 105 patients), we found similarities regarding blood metabolite temporal courses and associations with HAP (18%, 28% and 40% of HAP, respectively). Moreover, the probability of being discharged alive from the ICU with interferon gamma-1b was decreased in patients with low-risk metabolic response patterns and increased in patients with high-risk metabolic response patterns.

CONCLUSIONS: Longitudinal clustering classified metabolic response patterns into low-, moderate-, and high-risk groups for HAP and can help identify responders and non-responders to interferon gamma-1b after a single treatment injection.

TRIAL REGISTRATION: Number clinicaltrial.gov NCT02003196 and NCT04793568.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Petrier M, Sinha D, Martin FP, et al. Identification of a robust metabolic signature associated with hospital-acquired pneumonia and response to interferon-gamma treatment in critically ill patients. Crit Care. 2026. PMID: 41820963. doi:10.1186/s13054-026-05946-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。